Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
---|---|---|---|---|---|---|---|---|---|---|
|
T | 0.700 | CausalMutation | CLINVAR | Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. | 20921465 | 2010 |
|||
|
T | 0.700 | CausalMutation | CLINVAR | Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. | 19679400 | 2009 |
|||
|
C | 0.700 | GeneticVariation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |
|||
|
T | 0.700 | CausalMutation | CLINVAR | Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. | 18316791 | 2008 |
|||
|
T | 0.700 | CausalMutation | CLINVAR | Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | 20921462 | 2010 |
|||
|
T | 0.700 | CausalMutation | CLINVAR | Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. | 19114683 | 2009 |
|||
|
T | 0.700 | CausalMutation | CLINVAR | KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | 16618717 | 2006 |
|||
|
T | 0.700 | CausalMutation | CLINVAR | Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. | 16361624 | 2005 |
|||
|
T | 0.700 | CausalMutation | CLINVAR | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. | 21228335 | 2011 |
|||
|
T | 0.700 | CausalMutation | CLINVAR | Prospective enterprise-level molecular genotyping of a cohort of cancer patients. | 25157968 | 2014 |